Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino D, Abrahamsson N, Davies M, et al. JAMA 2021;325:1414-1425.
What it found
After everyone lost a mean 10.6% in the run-in, those who continued semaglutide lost a further 7.9% while those switched to placebo regained 6.9% (difference 14.8 percentage points). Gastrointestinal events: 49.1% with continued semaglutide vs 26.1% with placebo.
Limitations
Only people who tolerated the full dose in the run-in were randomised, which favours the drug. Adults without diabetes; lifestyle intervention in both groups.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.